Subscribe to
our newsletters

Subscribe to our newsletters!

Subscribe to our newsletter and get the latest news from the Nordics straight to your inbox.

Search in Nordic Life Science Insight

Abigo Medical AB logo

Abigo Medical AB

– An entrepreneurial and fast-growing Swedish pharmaceutical company

ABIGO is a complete pharmaceutical company with integrated R&D, manufacturing and marketing. The headquarters are located in Gothenburg, where we also have our dedicated research laboratory. We have our own manufacturing facility in Askersund. ABIGO has 140 employees and an annual revenue of approximately SEK 300 million.

ABIGO operates two business areas; pharmaceuticals, and medical devices. The pharmaceutical division comprises a broad range of both prescription- and OTC products while the medical devices division consists of an advanced wound care product line and ENT (earnosethroat) products.

ABIGO is focused internationally with an extensive distribution network. In Sweden, Norway, Finland and Denmark ABIGO has its own marketing and sales subsidiaries while through a global network of distributors our products are sold in over 70 countries worldwide. The international growth rate of ABIGO is significant and will continue to improve. As a dynamic and flexible company with a flat organizational structure ABIGO is positioned to make rapid decisions when assessing emerging opportunities. We actively seek to engage new technology in exciting and new fields and to identify development opportunities. This enables ABIGO to develop innovative products that benefit a great number of people. The foundation of our research program is curiosity and the desire to develop unique, efficient and safe products. Our research program is an important investment to ensure our sustained future growth and strength.

Our development program and product range is focused on innovative and preferably patent-covered products with international potential.

A focus area and a research priority for ABIGO is infection control.

There is a high risk that within ten years bacteria will develop resistance to most of the currently used antibiotics. International experts agree that the use of antibiotics must be reduced and other alternatives must be developed, a goal that ABIGO shares and will continue to contribute toward.

Our qualified team of researchers is working to develop tomorrow’s products for infection control. A global network of experts, universities and institutes are intrinsically linked to ABIGOs´ research program, a logical collaboration when pursuing optimum health outcomes.

‍Candida albicans binds to Sorbact® surface

Sorbact® is a Swedish innovation based on the research results of two leading Swedish professors. The proprietary Sorbact(R) tehnology acts to mimic a natural process that binds and inactivates pathogenic microorganisms without any known side effects.

The largest and most successful application of ABIGOs´ Sorbact® method is in advanced wound management where a broad portfolio of products has been developed.

Advanced wound mangement currently struggles with bacteria resistance to both antibiotic and antiseptic preparations. The increased antibiotic burden leads to greater costs and a negative environmental impact when these wound products are disposed of.

In contrast, the Sorbact® wound management line offers an effective, safe and environmentally friendly wound healing process. In addition to this, no known side effects or risk of microorganism resistance development has ever been demonstrated, a truly unique combination.

Sorbact® microbe-binding dressings prevent and treat wound infections by lowering the bioburden naturally. Microorganisms bind to the dressing surface and are removed when the dressing is changed.

The Sorbact® technology effectively binds bacteria, including multidrug-resistant bacteria such as MRSA. Sorbact® will also bind fungi to its surface and thus further reduce the overall bioburden of the wound. Sorbact® is positioned to both manage infected wounds and prevent wound infections without relying on the use of cytotoxic agents. This is important to consider when attempting to decrease the global trend of bacterial resistance.

A recently published randomized, controlled clinical study in 543 patients showed that the risk of surgical site infection after cesarean section is significantly reduced when using Sorbact® Surgical Dressing, compared to a standard dressing. The surgical site infections that nevertheless occurred also had a milder course and required less postoperative treatment resulting in a clearly improved cost-effectiveness.

ABIGO is a family owned company, The company was founded in 1989 by the current owners, brothers Jan G. Smith and Leif Smith, both still actively involved in the ABIGO management.

”Research and development, innovative & unique products, globalization, growth and sustainability” are the key words for the company.

‍Wound microorganisms bind to Sorbact® surface

Sorbact® products are manufactured in ABIGOs´ factory located in Askersund. It is Sweden’s only factory for the manufacturing of advanced wound healing products. Dedicated staff with comprehensive skills and experience guarantees the quality of all our products. In addition, the plant assists in our product development, including our inhouse design of production equipment. Investments in efficiency ensure that capacity is maintained in keeping up with our product’s dramatic expansion, a result credited to the rational and efficient frontline manufacturing. In 2016 the Askersund plant was significantly expanded to a total of 5000 sqm, an investment of more than SEK 30 millions.

Quality assurance is important to ABIGO who is certified under ISO 9001:2018 (quality), ISO 14001:2018 (environment) and ISO 13485:2018 (medical devices). As a pharmaceutical company ABIGO is also regulated by the Swedish Medical Products Agency.

ABIGO participates at international exhibitions, for example the annual EWMA congress of which we are also a B-sponsor. EWMA (European Wound Management Association), founded in 1991, works by linking wound management associations across Europe and brings together individuals and organizations interested in wound management. In addition to being an educational resource, EWMA organizes conferences, contributes to international projects related to wounds and provides a wide range of information. ABIGO feels that this is a meaningful sponsorship for the company.

ABIGO Medical is an excellent example of Swedish innovations leading to more jobs and steady growth in turnover for the company. Increased exports also lead to greater prosperity.

Get in touch with us!

Visit us

Ekonomivägen 5,
SE-436 33
Askim

Send us mail

Ekonomivägen 5, SE-436 33 Askim

Our published articles

No items found.
Date
Title
Category
No articles found.
Abigo Medical AB

Abigo Medical AB

– An entrepreneurial and fast-growing Swedish pharmaceutical company

ABIGO is a complete pharmaceutical company with integrated R&D, manufacturing and marketing. The headquarters are located in Gothenburg, where we also have our dedicated research laboratory. We have our own manufacturing facility in Askersund. ABIGO has 140 employees and an annual revenue of approximately SEK 300 million.

ABIGO operates two business areas; pharmaceuticals, and medical devices. The pharmaceutical division comprises a broad range of both prescription- and OTC products while the medical devices division consists of an advanced wound care product line and ENT (earnosethroat) products.

ABIGO is focused internationally with an extensive distribution network. In Sweden, Norway, Finland and Denmark ABIGO has its own marketing and sales subsidiaries while through a global network of distributors our products are sold in over 70 countries worldwide. The international growth rate of ABIGO is significant and will continue to improve. As a dynamic and flexible company with a flat organizational structure ABIGO is positioned to make rapid decisions when assessing emerging opportunities. We actively seek to engage new technology in exciting and new fields and to identify development opportunities. This enables ABIGO to develop innovative products that benefit a great number of people. The foundation of our research program is curiosity and the desire to develop unique, efficient and safe products. Our research program is an important investment to ensure our sustained future growth and strength.

Our development program and product range is focused on innovative and preferably patent-covered products with international potential.

A focus area and a research priority for ABIGO is infection control.

There is a high risk that within ten years bacteria will develop resistance to most of the currently used antibiotics. International experts agree that the use of antibiotics must be reduced and other alternatives must be developed, a goal that ABIGO shares and will continue to contribute toward.

Our qualified team of researchers is working to develop tomorrow’s products for infection control. A global network of experts, universities and institutes are intrinsically linked to ABIGOs´ research program, a logical collaboration when pursuing optimum health outcomes.

‍Candida albicans binds to Sorbact® surface

Sorbact® is a Swedish innovation based on the research results of two leading Swedish professors. The proprietary Sorbact(R) tehnology acts to mimic a natural process that binds and inactivates pathogenic microorganisms without any known side effects.

The largest and most successful application of ABIGOs´ Sorbact® method is in advanced wound management where a broad portfolio of products has been developed.

Advanced wound mangement currently struggles with bacteria resistance to both antibiotic and antiseptic preparations. The increased antibiotic burden leads to greater costs and a negative environmental impact when these wound products are disposed of.

In contrast, the Sorbact® wound management line offers an effective, safe and environmentally friendly wound healing process. In addition to this, no known side effects or risk of microorganism resistance development has ever been demonstrated, a truly unique combination.

Sorbact® microbe-binding dressings prevent and treat wound infections by lowering the bioburden naturally. Microorganisms bind to the dressing surface and are removed when the dressing is changed.

The Sorbact® technology effectively binds bacteria, including multidrug-resistant bacteria such as MRSA. Sorbact® will also bind fungi to its surface and thus further reduce the overall bioburden of the wound. Sorbact® is positioned to both manage infected wounds and prevent wound infections without relying on the use of cytotoxic agents. This is important to consider when attempting to decrease the global trend of bacterial resistance.

A recently published randomized, controlled clinical study in 543 patients showed that the risk of surgical site infection after cesarean section is significantly reduced when using Sorbact® Surgical Dressing, compared to a standard dressing. The surgical site infections that nevertheless occurred also had a milder course and required less postoperative treatment resulting in a clearly improved cost-effectiveness.

ABIGO is a family owned company, The company was founded in 1989 by the current owners, brothers Jan G. Smith and Leif Smith, both still actively involved in the ABIGO management.

”Research and development, innovative & unique products, globalization, growth and sustainability” are the key words for the company.

‍Wound microorganisms bind to Sorbact® surface

Sorbact® products are manufactured in ABIGOs´ factory located in Askersund. It is Sweden’s only factory for the manufacturing of advanced wound healing products. Dedicated staff with comprehensive skills and experience guarantees the quality of all our products. In addition, the plant assists in our product development, including our inhouse design of production equipment. Investments in efficiency ensure that capacity is maintained in keeping up with our product’s dramatic expansion, a result credited to the rational and efficient frontline manufacturing. In 2016 the Askersund plant was significantly expanded to a total of 5000 sqm, an investment of more than SEK 30 millions.

Quality assurance is important to ABIGO who is certified under ISO 9001:2018 (quality), ISO 14001:2018 (environment) and ISO 13485:2018 (medical devices). As a pharmaceutical company ABIGO is also regulated by the Swedish Medical Products Agency.

ABIGO participates at international exhibitions, for example the annual EWMA congress of which we are also a B-sponsor. EWMA (European Wound Management Association), founded in 1991, works by linking wound management associations across Europe and brings together individuals and organizations interested in wound management. In addition to being an educational resource, EWMA organizes conferences, contributes to international projects related to wounds and provides a wide range of information. ABIGO feels that this is a meaningful sponsorship for the company.

ABIGO Medical is an excellent example of Swedish innovations leading to more jobs and steady growth in turnover for the company. Increased exports also lead to greater prosperity.

Get in touch with us!

Visit us

Ekonomivägen 5,
SE-436 33
Askim

Send us mail

Ekonomivägen 5, SE-436 33 Askim

Our published articles

No items found.
Date
Title
Category
No articles found.